The
therapeutic effect of
mefenamic acid,
prostaglandin synthesis inhibitor, on
pain of acute menstrual
migraine and at the following days during menstrual
bleeding period was studied and compared with placebo. 24 patients, 18 to 35 years old, with menstrual
migraine were entered for study. They had regular menstrual cycles and they had been diagnosed as experiencing menstrual
migraine without aura for more than one year. The patients were treated for 2 consecutive menstrual cycles, one cycle with 500 mg
mefenamic acid and one cycle with placebo. Each
drug was given at beginning of complaint and similar dose was repeated 8 hourly at following days during the menstrual
bleeding period (Total dosage used 1500 mg per day). The use of medication was double blind.
Pain intensity was rated by means of a 4 points scale and functional disability was rated from 0 to 3. Results showed that 79.16% of the patients showed significant
pain relief with
mefenamic acid as compared to 16.6% with placebo. The mean
pain score of the
mefenamic acid treated attacks decreased significantly from 2.46 +/- 0.5 to 0.62 +/- 1.0 at 2hr postdose. 83.3% of patients treated with
mefenamic acid was able to function with or without little effort whereas 12.4% restored their activities with placebo. All the patients (100%) who showed significant initial responses to placebo experienced
headache recurrence as compared to 26.3% with
mefenamic acid. When considering mean
pain scores, percentage of patients with
pain free at 2h postdose, percentage of patients required rescue treatment, percentage of patients with
headache recurrence and percentages of patients restored full activities,
mefenamic acid is significantly superior to placebo in treatment of acute menstrual
migraine. It might be concluded that
mefenamic acid is safe and effective for treatment of acute menstrual
migraine.